Acorda Therapeutics Inc

Most Recent

  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”

    By Kenneth Smith
  • uploads///ALKS
    Company & Industry Overviews

    A Look at Alkermes’ Diabetes Product Portfolio

    According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.